Chronic Spontaneous Urticaria Clinical Trials

23 recruitingLast updated: May 13, 2026

There are 23 actively recruiting chronic spontaneous urticaria clinical trials across 25 countries. Studies span Phase 2, Phase 3, Phase 1, Phase 4. Top locations include Guangzhou, Guangdong, China, Toledo, Ohio, United States, Birmingham, Alabama, United States. Updated daily from ClinicalTrials.gov.


Chronic Spontaneous Urticaria Trials at a Glance

23 actively recruiting trials for chronic spontaneous urticaria are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Guangzhou, Toledo, and Birmingham. Lead sponsors running chronic spontaneous urticaria studies include Novartis Pharmaceuticals, Celldex Therapeutics, and Blueprint Medicines Corporation.

Browse chronic spontaneous urticaria trials by phase

Treatments under study

About Chronic Spontaneous Urticaria Clinical Trials

Looking for clinical trials for Chronic Spontaneous Urticaria? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chronic Spontaneous Urticaria trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chronic Spontaneous Urticaria clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 3

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria
Novartis Pharmaceuticals100 enrolled65 locationsNCT05677451
Recruiting
Phase 2

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Novartis Pharmaceuticals44 enrolled17 locationsNCT06865651
Recruiting
Phase 3

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Celldex Therapeutics1,370 enrolled20 locationsNCT07256392
Recruiting
Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

Chronic Spontaneous UrticariaChronic Inducible Urticaria
Enanta Pharmaceuticals, Inc98 enrolled1 locationNCT07540910
Recruiting
Phase 2Phase 3

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria (CSU)
Beijing InnoCare Pharma Tech Co., Ltd.344 enrolled30 locationsNCT07378527
Recruiting

A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Sanofi400 enrolled1 locationNCT07316114
Recruiting

Remibrutinib in Real-world Clinical Practice

Chronic Spontaneous Urticaria
Novartis Pharmaceuticals3,280 enrolled1 locationNCT07358364
Recruiting
Phase 2

Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines

Chronic Spontaneous Urticaria (CSU)Allergic Diseases
Yuhan Corporation150 enrolled30 locationsNCT07415551
Recruiting
Phase 2

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

Chronic Spontaneous Urticaria
Pfizer200 enrolled52 locationsNCT07219615
Recruiting
Phase 2

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

Chronic Spontaneous Urticaria (CSU)
Keymed Biosciences Co.Ltd48 enrolled1 locationNCT07166211
Recruiting
Phase 3

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Chronic Spontaneous Urticaria (CSU)
Novartis Pharmaceuticals400 enrolled114 locationsNCT06868212
Recruiting

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Chronic Spontaneous Urticaria
Novartis Pharmaceuticals350 enrolled1 locationNCT07408219
Recruiting
Phase 2

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous UrticariaChronic Inducible Urticaria
Blueprint Medicines Corporation105 enrolled47 locationsNCT06931405
Recruiting

ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar

Chronic Spontaneous Urticaria (CSU)Allergic Asthma
Celltrion HealthCare France225 enrolled1 locationNCT07425639
Recruiting

Remibrutinib in Real-world Clinical Practice - a US Sub-study

Chronic Spontaneous Urticaria
Novartis Pharmaceuticals505 enrolled1 locationNCT07358780
Recruiting
Phase 2

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria
Evommune, Inc.160 enrolled53 locationsNCT06873516
Recruiting

Analysis of the Role of IgE Proteoforms in Health and Disease

AnaphylaxisHealthy ControlMastocytosis+6 more
KU Leuven200 enrolled1 locationNCT07328178
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes

Chronic Spontaneous Urticaria
Chengdu Suncadia Medicine Co., Ltd.66 enrolled1 locationNCT07230418
Recruiting
Phase 3

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Taizhou Mabtech Pharmaceutical Co.,Ltd392 enrolled1 locationNCT06365879
Recruiting
Phase 4

Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous UrticariaChronic Urticaria, Idiopathic
Simon Francis Thomsen40 enrolled1 locationNCT05916937